A Study of the Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Features of Atypical/Dysplastic Nevi in Patients With Stage IIB-IIIC Melanoma
This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi.
• Subjects must have at least two atypical nevi of ≥ 4 mm diameter.
• Subjects must have a current documented history of melanoma.
• Subject must be ≥ 18 years and if female of childbearing potential, must agree to practice effective contraception per institutional SOC if sexually active.
• Subjects will have been deemed candidates for adjuvant therapy with single agent anti-PD1 therapy.
• Subjects must give written informed consent to participate in this study with consent signed and dated prior to entry into trial.